Dup15q Syndrome Market

Aug 10, 2020

20 likes | 28 Views

The total prevalent cases of Dup15q Syndrome in the 7MM was found to be 45,884 in 2017. The prevalence of Dup15q syndrome in the United States was 22,077 in 2017. The market size of Dup15q syndrome in the 7MM was USD 15.69 Million in 2017, according to DelveInsight, Dup15q syndrome market in the 7MM is expected to change in the study period 2017u20132030. Identification of electroencephalogram (ECG) biomarkers, support and awareness from disease advocacy groups, expected launch of soticlestat are some of the key factors expected to drive the Dup15q syndrome market forward in the coming years. Most of the patients suffering from the Dup15q syndrome show a variety of symptoms, and the current treatment approach helps in managing them. The choice of treatment to be adopted depends on the type of symptoms the person is showing. Some of the key players in the therapeutic development of Dup15q syndrome include Ovid Therapeutics, Takeda and others. For more details on Dup15q syndrome market, visit: https://www.delveinsight.com/report-store/dup15q-syndrome-market-forecast

DelveInsight

Download Presentation

Dup15q Syndrome Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D